Annonce • May 14
Converium Capital Sends Letter to CVS Group On May 13, 2026, Converium Capital Inc. announced that it has sent a letter to CVS Group Plc's Board of Directors highlighting the Company's undervaluation and urging the immediate initiation of a £100 million share buyback, equivalent to 12.5% of the Company's current market capitalization. In addition, Converium says a buyback is the highest-return use of capital currently available, the Company has capacity to fund it, and Converium stating that it remains available to discuss, and it is continuing its dialogue with other shareholders in the meantime. Annonce • Apr 23
Cvs Group plc Announces Appointment of Laura Hagan as Independent Non-Executive Director, Effective May 1, 2026 CVS Group plc announced the appointment of Laura Hagan as an Independent Non-Executive Director with effect from May 1, 2026. Laura is presently an Independent Non-Executive Director and Chair of the Remuneration Committee at FeverTree Drinks plc and was, until March 2026, Chief People Officer at Deliveroo plc. Laura's earlier executive roles include Chief People Officer at Gymshark Ltd, Chief HR Officer at Tate & Lyle plc and Group HR Director at Dyson Ltd. Laura has a wealth of experience in people leadership, organisation design optimisation, international expansion and the delivery of customer driven service through technology. Laura's blend of experience operating in both FTSE 250 and fast growth privately owned companies will add value to the board. From the date of her appointment, Laura will become a member of the Group's Remuneration Committee, Audit and Risk Committee and Nomination Committee. Laura's appointment, following that of Helen Keays and Jane Bednall announced on March 25, 2026, adds complementary skills and experience to the Board through her extensive listed company experience and her expertise in people development, leadership, customer service and international expansion. Annonce • Mar 25
CVS Group plc Announces Board and Committee Changes CVS Group plc announced the appointment of Helen Keays and Jane Bednall as Independent Non-Executive Directors with effect from 1 April 2026, the retirement of Deborah Kemp with effect from 30 June 2026 and a change in Chair of the Group's Nomination Committee. Deborah Kemp, who joined the board in January 2018 and who is presently Senior Independent Director and Chair of the Remuneration Committee will retire and step down from the Board and all board committees on 30 June 2026. Helen Keays is presently an Independent Non-Executive Director and Chair of the Remuneration Committee at Nichols plc following an executive career in consumer-facing multi-site businesses across retail, mobile telecommunications and retail financial services. Helen has worked at Vodafone plc, latterly as General Manager of Singlepoint, and previously at Sears plc. Helen has previously been an Independent Non-Executive Director of The Restaurant Group, Domino's Pizza UK & Ireland, Communisis plc, Majestic Wine plc, Mattioli Woods plc and Chrysalis Group plc. Helen is an experienced Non-Executive Director and Remuneration Committee Chair and will add value to the board through her expertise in people development, consumer marketing and CRM. From the date of her appointment, Helen Keays will become Chair Designate of the Remuneration Committee and will also become a member of the Group's Audit and Risk Committee and Nomination Committee. Helen will formally become Chair of the Remuneration Committee with effect from 1 July 2026. Jane Bednall is presently an Independent Non-Executive Director of Fuller Smith & Turner plc and Independent Non-Executive Director and Chair of the Remuneration, People and Culture Committee for The Kings Cross Group, appointed on behalf of AustralianSuper, Australia's largest pension fund. This follows an executive career in senior leadership roles at British Airways, InterContinental Hotel Group (IHG), Centrica and most recently SSE plc where she was Chief Marketing Officer and formerly Managing Director of Retail Energy. Jane was previously Non-Executive Director of DFS plc, EI Group plc and Smart Energy GB. Jane will add value to the board through her experience in multi-site retail and leisure businesses and her expertise in branding, consumer behaviour and insights. From the date of her appointment, Jane will become a member of the Group's Remuneration Committee, Audit and Risk Committee and Nomination Committee. David Wilton, Chair of CVS, will succeed Richard Gray as Chair of the Nominations Committee with effect from 1 April 2026. Annonce • Oct 24
CVS Group plc (AIM:CVSG) announces an Equity Buyback for £20 million worth of its shares. CVS Group plc (AIM:CVSG) announces an share repurchase program. Under the program, the company will repurchases up to £20 million. The purpose of the Share Buyback Program is to both return surplus capital to shareholders and reduce the Group's share capital pursuant to its capital allocation policy. As such, all Ordinary Shares repurchased by the Group under the Share Buyback Program will be cancelled. The program will valid till Q1 of calendar year 2026. Annonce • May 20
Anima Care UK Limited acquired Crematoria operations of CVS Group plc (AIM:CVSG) for £42.4 million. Anima Care UK Limited agreed to acquire Crematoria operations of CVS Group plc (AIM:CVSG) for £42.4 million on April 24, 2025. A cash consideration of £42.4 million will be paid by Anima Care UK Limited. As part of consideration, £42.4 million is paid towards assets of Crematoria operations of CVS Group plc. As part of the acquisition, Funecap will provide clinical waste disposal and cremation services to CVS practices and clients following completion. The capital generated from the divestment provides additional firepower for continued selective investment in the UK and expansion in Australia. The capital recycling is expected to be value accretive to the Group in due course and allows CVS to focus on its core veterinary and diagnostics services.
For the period ending December 31, 2024, Crematoria operations of CVS Group plc reported total revenue of £12 million and EBITDA of £4.3 million. As of December 31, 2024, Crematoria operations of CVS Group plc reported total common equity of £23.6 million.
The expected completion date of the transaction is within the next five weeks.
Anima Care UK Limited completed the acquisition of Crematoria operations of CVS Group plc (AIM:CVSG) on May 19, 2025. In related transaction, CVS Group plc completed the acquisition of VPP Group. Christopher Golden, James Steel and Andrew Clark of Peel Hunt LLP acted as financial advisor for CVS Group plc. Toby Flaux, Michael Burke, James Thompson and Milo Bonser brokered the transaction. Annonce • Apr 25
Anima Care UK Limited agreed to acquire Crematoria operations of CVS Group plc (AIM:CVSG) for £42.4 million. Anima Care UK Limited agreed to acquire Crematoria operations of CVS Group plc (AIM:CVSG) for £42.4 million on April 24, 2025. A cash consideration of £42.4 million will be paid by Anima Care UK Limited. As part of consideration, £42.4 million is paid towards assets of Crematoria operations of CVS Group plc. As part of the acquisition, Funecap will provide clinical waste disposal and cremation services to CVS practices and clients following completion. The capital generated from the divestment provides additional firepower for continued selective investment in the UK and expansion in Australia. The capital recycling is expected to be value accretive to the Group in due course and allows CVS to focus on its core veterinary and diagnostics services.
For the period ending December 31, 2024, Crematoria operations of CVS Group plc reported total revenue of £12 million and EBITDA of £4.3 million. As of December 31, 2024, Crematoria operations of CVS Group plc reported total common equity of £23.6 million.
The expected completion date of the transaction is within the next five weeks. Annonce • Nov 20
CVS Group plc Proposes Final Dividend, Payable on 29 November 2024 Subject to shareholder approval at the AGM, CVS Group plc intends to pay its previously announced final dividend of 8.0 pence per ordinary share on 29 November 2024 to holders on the register as at 1 November 2024. The ex-dividend date was 31 October 2024. Upcoming Dividend • Oct 24
Upcoming dividend of UK£0.08 per share Eligible shareholders must have bought the stock before 31 October 2024. Payment date: 29 November 2024. Payout ratio is a comfortable 22% and this is well supported by cash flows. Trailing yield: 0.9%. Lower than top quartile of German dividend payers (4.9%). Lower than average of industry peers (2.9%). Declared Dividend • Sep 29
Dividend of UK£0.08 announced Shareholders will receive a dividend of UK£0.08. Ex-date: 31st October 2024 Payment date: 29th November 2024 Dividend yield will be 0.6%, which is lower than the industry average of 3.3%. Sustainability & Growth Dividend is well covered by both earnings (22% earnings payout ratio) and cash flows (23% cash payout ratio). The dividend has increased by an average of 12% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 67% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • Sep 26
Full year 2024 earnings released: EPS: UK£0.36 (vs UK£0.59 in FY 2023) Full year 2024 results: EPS: UK£0.36 (down from UK£0.59 in FY 2023). Revenue: UK£647.3m (up 6.4% from FY 2023). Net income: UK£26.2m (down 38% from FY 2023). Profit margin: 4.0% (down from 6.9% in FY 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 6.1% p.a. on average during the next 3 years, compared to a 3.6% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings. Recent Insider Transactions • Jun 30
Independent Non-Executive Chairman recently bought €3.1m worth of stock On the 25th of June, David Wilton bought around 3k shares on-market at roughly €1,246 per share. This transaction amounted to 38% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was David's only on-market trade for the last 12 months. Annonce • Jun 19
CVS Group plc Announces Resignation of Ben Jacklin as Executive Director CVS Group plc announces that Ben Jacklin, Executive Director, has resigned. Ben's managerial and operational responsibilities, including the provision of clinical guidance to the Board, have been assumed by other senior members of the Group. Board Change • May 16
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Non Executive Director Joanne Shaw was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Annonce • May 01
CVS Group plc Announces Board Changes CVS Group plc announced the appointment of David Wilton as Chair with effect from 1 May 2024. David has served as an Independent Non-executive Director of the Company since September 2021. David is a qualified Chartered Accountant with more than 30 years' post-qualification experience as a Chief Financial Officer, Non-Executive Director (NED), Chair and consultant after many years in corporate finance, primarily in mid-cap M&A with Rothschilds. David has held roles in both public and private-equity backed companies including as CFO of Sumo Group plc, Group Finance Director of WYG plc and NED and Chair of the Audit Committee of Sweett Group plc. David was NED and subsequently Chair at Frontier Developments plc until November 2023. David is currently also NED and Chair Designate at Gateley (Holdings) plc. He has extensive experience of people businesses and of regulatory processes. David also brings to the Chair role a significant amount of technical expertise, which will support CVS in its strategic delivery of investment in technology. David Wilton's appointment follows a comprehensive search by the Nomination Committee, supported by a blue chip recruitment firm who sourced a number of high quality candidates. The Board would like to thank Deborah Kemp, the Group's Senior Independent Director who has been acting as Interim Chair during the search period. David will remain as Audit Committee Chair until this process is completed, at which point he will then step down as a member of the Audit Committee. Valuation Update With 7 Day Price Move • Mar 13
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to €13.40, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 13x in the Healthcare industry in Germany. Total loss to shareholders of 37% over the past three years. Reported Earnings • Mar 04
First half 2024 earnings released: EPS: UK£0.20 (vs UK£0.30 in 1H 2023) First half 2024 results: EPS: UK£0.20 (down from UK£0.30 in 1H 2023). Revenue: UK£329.9m (up 11% from 1H 2023). Net income: UK£14.6m (down 31% from 1H 2023). Profit margin: 4.4% (down from 7.1% in 1H 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.8% p.a. on average during the next 3 years, while revenues in the Healthcare industry in Germany are expected to remain flat. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Annonce • Oct 27
CVS Announce Director Changes CVS announced that its Chair Richard Connell has taken the difficult decision to resign with immediate effect due to ill health. Deborah Kemp, the Group's Senior Independent Director will assume the role of Chair for the interim period whilst the Board commences a process to appoint a permanent successor. Upcoming Dividend • Oct 26
Upcoming dividend of UK£0.075 per share at 0.5% yield Eligible shareholders must have bought the stock before 02 November 2023. Payment date: 08 December 2023. Payout ratio is a comfortable 13% and this is well supported by cash flows. Trailing yield: 0.5%. Lower than top quartile of German dividend payers (5.1%). Lower than average of industry peers (3.5%). Reported Earnings • Sep 21
Full year 2023 earnings released: EPS: UK£0.59 (vs UK£0.36 in FY 2022) Full year 2023 results: EPS: UK£0.59 (up from UK£0.36 in FY 2022). Revenue: UK£608.3m (up 9.8% from FY 2022). Net income: UK£41.9m (up 63% from FY 2022). Profit margin: 6.9% (up from 4.6% in FY 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.2% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth. Annonce • Sep 21
CVS Group plc Recommends Final Dividend, Payable on 8 December 2023 CVS Group plc recommends continuation of progressive dividend policy, with the payment of a final dividend of 7.5 pence per Ordinary share (2022: 7.0 pence). The ex-dividend date is 2 November 2023 and the dividend payment date is 8 December 2023. Valuation Update With 7 Day Price Move • Sep 08
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to €19.70, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 18x in the Healthcare industry in Germany. Total returns to shareholders of 57% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €28.55 per share. Buying Opportunity • Sep 07
Now 26% undervalued after recent price drop Over the last 90 days, the stock is down 16%. The fair value is estimated to be €26.90, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 42%. For the next 3 years, revenue is forecast to grow by 6.5% per annum. Earnings is also forecast to grow by 19% per annum over the same time period. Reported Earnings • Feb 26
First half 2023 earnings released: EPS: UK£0.30 (vs UK£0.25 in 1H 2022) First half 2023 results: EPS: UK£0.30 (up from UK£0.25 in 1H 2022). Revenue: UK£296.3m (up 8.3% from 1H 2022). Net income: UK£21.1m (up 21% from 1H 2022). Profit margin: 7.1% (up from 6.4% in 1H 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 5.4% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth. Annonce • Nov 23
CVS Group plc Recommends Dividend, Payable on 2 December 2022 CVS Group plc announced that as previously announced, and subject to shareholder approval at the AGM, the company intends to pay a dividend of 7.0 pence per ordinary share on 2 December 2022 to holders on the register as at 18 November 2022. The ex-dividend date for this timetable is 17 November 2022. Buying Opportunity • Nov 11
Now 21% undervalued Over the last 90 days, the stock is up 2.9%. The fair value is estimated to be €27.44, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 43%. For the next 3 years, revenue is forecast to grow by 5.7% per annum. Earnings is also forecast to grow by 18% per annum over the same time period. Upcoming Dividend • Nov 10
Upcoming dividend of UK£0.07 per share Eligible shareholders must have bought the stock before 17 November 2022. Payment date: 02 December 2022. Payout ratio is a comfortable 19% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of German dividend payers (5.0%). Lower than average of industry peers (4.1%). Recent Insider Transactions • Sep 29
Independent Non-Executive Chairman recently bought €83k worth of stock On the 22nd of September, Richard Connell bought around 5k shares on-market at roughly €18.56 per share. This transaction amounted to 2.7% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Richard has been a buyer over the last 12 months, purchasing a net total of €256k worth in shares. Reported Earnings • Sep 23
Full year 2022 earnings released: EPS: UK£0.36 (vs UK£0.27 in FY 2021) Full year 2022 results: EPS: UK£0.36 (up from UK£0.27 in FY 2021). Revenue: UK£554.2m (up 8.6% from FY 2021). Net income: UK£25.7m (up 33% from FY 2021). Profit margin: 4.6% (up from 3.8% in FY 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 4.6% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth. Annonce • Jul 02
CVS Group plc (AIM:CVSG) acquired Ocvc Limited for £ 3 million. CVS Group plc (AIM:CVSG) acquired Ocvc Limited for £ 3 million on June 10, 2022. The consideration was funded from the Group's cash balances. Aubrey Powell, Jen Boorer, and Rachel Hayes of Singer Capital Markets Securities Limited acted as financial advisor to CVS Group plc.
CVS Group plc (AIM:CVSG) completed the acquisition of Ocvc Limited on June 10, 2022. Annonce • May 08
CVS Group plc (AIM:CVSG) acquired Anton Vets Ltd for £6 million. CVS Group plc (AIM:CVSG) acquired Anton Vets Ltd for £6 million on May 5, 2022. The consideration is being funded using the CVS Group's existing bank facilities. Aubrey Powell, Jen Boorer and Rachel Hayes of Singer Capital Markets Securities Limited acted as financial advisor to CVS Group plc.
CVS Group plc (AIM:CVSG) completed the acquisition of Anton Vets Ltd on May 5, 2022. Valuation Update With 7 Day Price Move • Feb 23
Investor sentiment deteriorated over the past week After last week's 16% share price decline to €18.75, the stock trades at a forward P/E ratio of 34x. Average forward P/E is 16x in the Healthcare industry in Germany. Total returns to shareholders of 260% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €34.78 per share. Recent Insider Transactions • Dec 09
Independent Non-Executive Chairman recently bought €63k worth of stock On the 6th of December, Richard Connell bought around 3k shares on-market at roughly €25.13 per share. In the last 3 months, they made an even bigger purchase worth €110k. Richard has been a buyer over the last 12 months, purchasing a net total of €278k worth in shares. Recent Insider Transactions • Nov 27
Independent Non-Executive Chairman recently bought €110k worth of stock On the 25th of November, Richard Connell bought around 4k shares on-market at roughly €26.17 per share. This was the largest purchase by an insider in the last 3 months. Richard has been a buyer over the last 12 months, purchasing a net total of €216k worth in shares. Upcoming Dividend • Nov 11
Upcoming dividend of UK£0.065 per share Eligible shareholders must have bought the stock before 18 November 2021. Payment date: 03 December 2021. Trailing yield: 0.3%. Lower than top quartile of German dividend payers (3.2%). Lower than average of industry peers (2.4%). Board Change • Nov 01
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Senior Independent Non-Executive Director Deborah Kemp was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Board Change • Oct 02
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Senior Independent Non-Executive Director Deborah Kemp was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Executive Departure • Oct 01
Senior Independent Non-Executive Director Michael McCollum has left the company On the 23rd of September, Michael McCollum's tenure as Senior Independent Non-Executive Director ended. As of June 2021, Michael still personally held 38.68k shares (€1.1m worth at the time). Michael is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.83 years, which is considered inexperienced in the Simply Wall St Risk Model. Reported Earnings • Sep 24
Full year 2021 earnings released: EPS UK£0.27 (vs UK£0.081 in FY 2020) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: UK£510.1m (up 19% from FY 2020). Net income: UK£19.3m (up 239% from FY 2020). Profit margin: 3.8% (up from 1.3% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has increased by 38% per year, which means it is tracking significantly ahead of earnings growth. Executive Departure • Sep 24
Senior Independent Non-Executive Director Michael McCollum has left the company On the 23rd of September, Michael McCollum's tenure as Senior Independent Non-Executive Director ended after 8.5 years in the role. As of June 2021, Michael still personally held 38.68k shares (€1.1m worth at the time). Michael is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.83 years, which is considered inexperienced in the Simply Wall St Risk Model. Annonce • May 01
CVS Group plc Provides Group Earnings Guidance for the Full Year Ending June 30, 2021 CVS Group plc provided earnings guidance for the full year ending June 30, 2021. This, coupled with the continued delivery of the vaccination programme and further easing of lockdown restrictions, means the Board is increasingly confident that this strong performance will continue for the remaining months of this financial year. Consequently, the Group now expects full year revenue to be ahead of current management expectations. Recent Insider Transactions • Mar 31
Non-Executive Director recently bought €66k worth of stock On the 29th of March, Richard Gray bought around 3k shares on-market at roughly €21.93 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months. Reported Earnings • Mar 26
First half 2021 earnings released: EPS UK£0.16 (vs UK£0.079 in 1H 2020) The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: UK£245.6m (up 9.4% from 1H 2020). Net income: UK£11.3m (up 102% from 1H 2020). Profit margin: 4.6% (up from 2.5% in 1H 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 25% per year, which means it is well ahead of earnings. Is New 90 Day High Low • Mar 11
New 90-day high: €20.62 The company is up 37% from its price of €15.06 on 10 December 2020. The German market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €25.14 per share. Is New 90 Day High Low • Jan 22
New 90-day high: €17.06 The company is up 25% from its price of €13.67 on 23 October 2020. The German market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is up 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €22.26 per share. Is New 90 Day High Low • Jan 05
New 90-day high: €16.96 The company is up 29% from its price of €13.18 on 07 October 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €22.75 per share. Is New 90 Day High Low • Dec 18
New 90-day high: €16.49 The company is up 32% from its price of €12.53 on 18 September 2020. The German market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €22.87 per share. Annonce • Nov 26
CVS Group plc Announces Appointment of Enrico Tizzano as its First Chief Technology Officer CVS Group plc announced that the Group has strengthened its management team with the appointment of Enrico Tizzano as its first Chief Technology Officer. Enrico will support the effective use of technology and data in delivery of the Group's strategic objectives and has a wealth of experience from previous CTO roles in large, consumer-facing organizations. Is New 90 Day High Low • Nov 05
New 90-day high: €14.38 The company is up 14% from its price of €12.57 on 07 August 2020. The German market is down 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €19.11 per share. Is New 90 Day High Low • Sep 28
New 90-day high: €13.89 The company is up 26% from its price of €11.06 on 30 June 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €12.81 per share. Reported Earnings • Sep 26
Full year earnings released - EPS €0.081 Over the last 12 months the company has reported total profits of UK£5.70m, down 31% from the prior year. Total revenue was UK£427.8m over the last 12 months, up 5.2% from the prior year. Profit margins were 1.3%, which is in line with last year. Annonce • Sep 24
CVS Group plc Not Propose Final Dividend The directors of CVS Group plc have proposed a final dividend of £nil (2019: 5.5 pence) per share, giving a total of £nil (2019: £3.9 million). During the year a dividend of 5.5 pence per share amounting to £3.9 million was paid (2019: £3.5 million).